Quarterly report pursuant to Section 13 or 15(d)

SEGMENT INFORMATION (Tables)

v3.23.1
SEGMENT INFORMATION (Tables)
6 Months Ended
Apr. 30, 2023
Segment Reporting [Abstract]  
SCHEDULE OF SEGMENT INFORMATION

  

    2023     2022     2023     2022  
    For the Three Months Ended
April 30,
    For the Six Months Ended
April 30,
 
    2023     2022     2023     2022  
Net income/(loss):                                
CAR-T Therapeutics   $ (997 )   $ (1,399 )   $ (1,908 )   $ (3,010 )
Cancer Vaccines     (913 )     (1,423 )     (1,871 )     (2,780 )
Anti-Viral Therapeutics     (416 )     (757 )     (898 )     (1,661 )
Other     19     (9 )     16     (16 )
Total   $ (2,307 )   $ (3,588 )   $ (4,661 )   $ (7,467 )
                                 
Total operating costs and expenses   $ 2,770     $ 3,589     $ 5,326     $ 7,469  
Less non-cash stock-based compensation     (1,227 )     (1,745 )     (2,290 )     (4,099 )
Operating costs and expenses excluding non-cash stock-based compensation   $ 1,543     $ 1,844     $ 3,036     $ 3,370  
Operating costs and expenses excluding non-cash stock-based compensation:                                
CAR-T Therapeutics   $ 620     $ 733     $ 1,218     $ 1,402  
Cancer Vaccines     523       716       1,111       1,196  
Anti-Viral Therapeutics     212       388       517       760  
Other     188       7       190       12  
Total   $ 1,543     $ 1,844     $ 3,036     $ 3,370  

 

    April 30,
2023
    October 31,
2022
 
Total assets:                
CAR-T Therapeutics   $ 11,682     $ 16,921  
Cancer Vaccines     10,638       9,442  
Anti-Viral Therapeutics    

4,953

      3,811  
Other    

326

      238  
Total   $ 27,599     $ 30,412